Ultime notizie per iShares MSCI UAE ETF (NASDAQ:UAE)

Financial Services

Real Estate

Communication Services

Industrials

Energy

Consumer Cyclical

Utilities

Consumer Defensive

Technology

Healthcare

The fund generally will invest at least 90% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is designed to measure the equity market in the United Arab Emirates (UAE). The fund is non-diversified.

Emaar Properties Pjsc

iShares MSCI UAE ETF

Throughout the last three months, 13 analysts have evaluated Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.85, a high estimate of $68.00, and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 32.7% increase from the previous average price target of $27.77.
<img src="https://www.benzinga.com/files/images/story/2025/1745618458_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Hims &amp; Hers Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Daniel Grosslight &#x7C;Citigroup &#x7C;Lowers &#x7C;Sell &#x7C; $25.00&#x7C;$27.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $33.00&#x7C;$39.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Underperform &#x7C; $22.00&#x7C;$21.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Maintains &#x7C;Underperform &#x7C; $21.00&#x7C;$21.00 &#x7C; 
&#x7C;Daniel Grosslight &#x7C;Citigroup &#x7C;Maintains &#x7C;Sell &#x7C; $27.00&#x7C;$27.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $39.00&#x7C;$24.00 &#x7C; 
&#x7C;Michael Cherny &#x7C;Leerink Partners &#x7C;Raises &#x7C;Market Perform &#x7C; $40.00&#x7C;$24.00 &#x7C; 
&#x7C;Korinne Wolfmeyer &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $35.00&#x7C;$24.00 &#x7C; 
&#x7C;Ryan MacDonald &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $61.00&#x7C;$31.00 &#x7C; 
&#x7C;Daniel Grosslight &#x7C;Citigroup &#x7C;Raises &#x7C;Sell &#x7C; $27.00&#x7C;$25.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Underperform &#x7C; $21.00&#x7C;$18.00 &#x7C; 
&#x7C;Maria Ripps &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $68.00&#x7C;$38.00 &#x7C; 
&#x7C;Craig Hettenbach &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $60.00&#x7C;$42.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hims &amp; Hers Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hims &amp; Hers Health compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Hims &amp; Hers Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hims &amp; Hers Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HIMS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hims &amp; Hers Health analyst ratings.</a>
<h2>All You Need to Know About Hims &amp; Hers Health</h2>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
<h3>Understanding the Numbers: Hims &amp; Hers Health's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Hims &amp; Hers Health's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 95.09%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Hims &amp; Hers Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.41%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Hims &amp; Hers Health's ROE stands out, surpassing industry averages. With an impressive ROE of 5.68%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Hims &amp; Hers Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.97% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Hims &amp; Hers Health's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Breaking Down Hims & Hers Health: 13 Analysts Share Their Views

Throughout the last three months, 17 analysts have evaluated Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Merit Medical Systems, revealing an average target of $114.12, a high estimate of $128.00, and a low estimate of $100.00. Observing a downward trend, the current average is 2.51% lower than the prior average price target of $117.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1745618451_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Merit Medical Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $108.00&#x7C;$127.00 &#x7C; 
&#x7C;Jayson Bedford &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $108.00&#x7C;$116.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Lowers &#x7C;Outperform &#x7C; $103.00&#x7C;$111.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $100.00&#x7C;$116.00 &#x7C; 
&#x7C;David Rescott &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $110.00&#x7C;$111.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $112.00&#x7C;$116.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $111.00&#x7C;$111.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $116.00&#x7C;$116.00 &#x7C; 
&#x7C;Robbie Marcus &#x7C;JP Morgan &#x7C;Announces &#x7C;Overweight &#x7C; $120.00&#x7C;- &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Lowers &#x7C;Outperform &#x7C; $111.00&#x7C;$115.00 &#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $127.00&#x7C;$128.00 &#x7C; 
&#x7C;Larry Biegelsen &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $117.00&#x7C;$120.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $116.00&#x7C;$122.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $116.00&#x7C;$114.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Raises &#x7C;Outperform &#x7C; $115.00&#x7C;$114.00 &#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $128.00&#x7C;$127.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $122.00&#x7C;$109.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Merit Medical Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Merit Medical Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Merit Medical Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Discovering Merit Medical Systems: A Closer Look</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Merit Medical Systems's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Merit Medical Systems displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 9.44%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Merit Medical Systems's net margin is impressive, surpassing industry averages. With a net margin of 7.87%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Merit Medical Systems's ROE stands out, surpassing industry averages. With an impressive ROE of 2.07%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Merit Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MMSI

The Analyst Verdict: Merit Medical Systems In The Eyes Of 17 Experts

In the last three months, 7 analysts have published ratings on Clearwater Analytics Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $34.71, a high estimate of $38.00, and a low estimate of $28.00. This upward trend is apparent, with the current average reflecting a 5.18% increase from the previous average price target of $33.00.
<img src="https://www.benzinga.com/files/images/story/2025/1745618443_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Clearwater Analytics Hldg among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Alexei Gogolev &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $28.00&#x7C;$33.00 &#x7C; 
&#x7C;Michael Turrin &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $32.00&#x7C;$35.00 &#x7C; 
&#x7C;James Faucette &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $36.00&#x7C;$34.00 &#x7C; 
&#x7C;Rishi Jaluria &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $36.00&#x7C;$30.00 &#x7C; 
&#x7C;Kevin Mcveigh &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $38.00&#x7C;$36.00 &#x7C; 
&#x7C;Michael Turrin &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $37.00&#x7C;$35.00 &#x7C; 
&#x7C;Arvind Ramnani &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $36.00&#x7C;$28.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clearwater Analytics Hldg. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Clearwater Analytics Hldg compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Clearwater Analytics Hldg's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Clearwater Analytics Hldg's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CWAN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Clearwater Analytics Hldg analyst ratings.</a>
<h2>Get to Know Clearwater Analytics Hldg Better</h2>
Clearwater Analytics Holdings Inc provides a SaaS solution for automated investment data aggregation, reconciliation, accounting and reporting services to insurers, investment managers, corporations, institutional investors and government entities. It earns revenue from providing access to its SaaS platform to customers, services that support the implementation on the SaaS platform, selling perpetual and term-based software licenses and providing maintenance and support and professional services under contracts with customers. The majority of the revenue is earned in the United States.
<h3>Breaking Down Clearwater Analytics Hldg's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Clearwater Analytics Hldg's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 27.72%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Clearwater Analytics Hldg's net margin excels beyond industry benchmarks, reaching 331.54%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 59.41%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Clearwater Analytics Hldg's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 46.77% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.07, Clearwater Analytics Hldg adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CWAN

Breaking Down Clearwater Analytics Hldg: 7 Analysts Share Their Views

IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $227.67, a high estimate of $270.00, and a low estimate of $160.00. Highlighting a 9.81% decrease, the current average has fallen from the previous average price target of $252.42. 
<img src="https://www.benzinga.com/files/images/story/2025/1745618435_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive IQVIA Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Rajesh Kumar &#x7C;HSBC &#x7C;Lowers &#x7C;Hold &#x7C; $160.00&#x7C;$260.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $216.00&#x7C;$263.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $170.00&#x7C;$235.00 &#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $210.00&#x7C;$242.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $210.00&#x7C;$225.00 &#x7C; 
&#x7C;Anne Samuel &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $232.00&#x7C;$240.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $250.00&#x7C;$245.00 &#x7C; 
&#x7C;Sean Dodge &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $270.00&#x7C;$270.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $263.00&#x7C;$261.00 &#x7C; 
&#x7C;Shlomo Rosenbaum &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $261.00&#x7C;$273.00 &#x7C; 
&#x7C;Dan Leonard &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $255.00&#x7C;$260.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $235.00&#x7C;$255.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IQVIA Hldgs. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IQVIA Hldgs compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of IQVIA Hldgs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of IQVIA Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IQV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on IQVIA Hldgs analyst ratings.</a>
<h2>All You Need to Know About IQVIA Hldgs</h2>
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
<h3>IQVIA Hldgs: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: IQVIA Hldgs's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.33%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.04%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.62%, the company showcases effective utilization of assets.
Debt Management: IQVIA Hldgs's debt-to-equity ratio stands notably higher than the industry average, reaching 2.33. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 12 Analysts Discuss IQVIA Hldgs Stock

CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) has been analyzed by 17 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CME Group, revealing an average target of $266.18, a high estimate of $305.00, and a low estimate of $211.00. Witnessing a positive shift, the current average has risen by 3.75% from the previous average price target of $256.56.
<img src="https://www.benzinga.com/files/images/story/2025/1745618427_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive CME Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Alex Kramm &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $305.00&#x7C;$290.00 &#x7C; 
&#x7C;Mike Cyprys &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $304.00&#x7C;$301.00 &#x7C; 
&#x7C;Kyle Voigt &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Market Perform &#x7C; $273.00&#x7C;$265.00 &#x7C; 
&#x7C;Kenneth Worthington &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $211.00&#x7C;$223.00 &#x7C; 
&#x7C;Benjamin Budish &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $283.00&#x7C;$279.00 &#x7C; 
&#x7C;Owen Lau &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $279.00&#x7C;$269.00 &#x7C; 
&#x7C;Patrick Moley &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $283.00&#x7C;$275.00 &#x7C; 
&#x7C;Benjamin Budish &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $279.00&#x7C;$263.00 &#x7C; 
&#x7C;Ashish Sabadra &#x7C;RBC Capital &#x7C;Maintains &#x7C;Sector Perform &#x7C; $269.00&#x7C;$269.00 &#x7C; 
&#x7C;Craig Siegenthaler &#x7C;B of A Securities &#x7C;Raises &#x7C;Underperform &#x7C; $219.00&#x7C;$200.00 &#x7C; 
&#x7C;Patrick O'Shaughnessy&#x7C;Raymond James &#x7C;Announces &#x7C;Outperform &#x7C; $287.00&#x7C;- &#x7C; 
&#x7C;Mike Cyprys &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $263.00&#x7C;$256.00 &#x7C; 
&#x7C;Kyle Voigt &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Market Perform &#x7C; $257.00&#x7C;$256.00 &#x7C; 
&#x7C;Ashish Sabadra &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $269.00&#x7C;$235.00 &#x7C; 
&#x7C;Owen Lau &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $269.00&#x7C;$258.00 &#x7C; 
&#x7C;Kenneth Worthington &#x7C;JP Morgan &#x7C;Raises &#x7C;Underweight &#x7C; $212.00&#x7C;$209.00 &#x7C; 
&#x7C;Benjamin Budish &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $263.00&#x7C;$257.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CME Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CME Group compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of CME Group's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CME/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CME Group analyst ratings.</a>
<h2>About CME Group</h2>
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&amp;P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&amp;P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
<h3>CME Group: Financial Performance Dissected</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: CME Group displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 7.67%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: CME Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 57.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.53%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CME Group's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.64%, the company may face hurdles in achieving optimal financial performance.
Debt Management: CME Group's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into CME Group Stock: Analyst Perspectives (17 Ratings)

In the current market session, Vulcan Materials Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) share price is at $247.04, after a 0.99% drop. Over the past month, the stock increased by 6.05%, but over the past year, it actually fell by 5.51%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1745618416_0.png" alt="Past Year Chart" />

<h3>How Does Vulcan Materials P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 16.13 in the Construction Materials industry, Vulcan Materials Inc. has a higher P/E ratio of 36.11. Shareholders might be inclined to think that Vulcan Materials Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745618416_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

A Look Into Vulcan Materials Inc's Price Over Earnings

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $36.25, along with a high estimate of $51.00 and a low estimate of $27.00. This current average has decreased by 12.65% from the previous average price target of $41.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1745618414_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Gentherm among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Luke Junk &#x7C;Baird &#x7C;Raises &#x7C;Neutral &#x7C; $28.00&#x7C;$27.00 &#x7C; 
&#x7C;Luke Junk &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $27.00&#x7C;$39.00 &#x7C; 
&#x7C;Luke Junk &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $39.00&#x7C;$44.00 &#x7C; 
&#x7C;Ryan Brinkman &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $51.00&#x7C;$56.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gentherm. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gentherm compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Gentherm's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Gentherm's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/THRM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gentherm analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Gentherm Better</h2>
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
<h3>A Deep Dive into Gentherm's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3M period, Gentherm faced challenges, resulting in a decline of approximately -3.82% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.34%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.4%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Gentherm's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.2%, the company showcases efficient use of assets and strong financial health.
Debt Management: Gentherm's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.43.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

THRM

Breaking Down Gentherm: 4 Analysts Share Their Views

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) has outperformed the market over the past 20 years by 8.67% on an annualized basis producing an average annual return of 16.74%. Currently, TJX Companies has a market capitalization of $142.53 billion. 
Buying $100 In TJX: If an investor had bought $100 of TJX stock 20 years ago, it would be worth $2,236.04 today based on a price of $126.79 for TJX at the time of writing.
<h3>TJX Companies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745618413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In TJX Companies 20 Years Ago Would Be Worth This Much Today

Scotiabank analyst Maher Yaghi maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Sector Perform and lowers the price target from $45 to $44.5.

Price Target

CMCSA

Scotiabank Maintains Sector Perform on Comcast, Lowers Price Target to $44.5

Scotiabank analyst Andrew Weisel maintains CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) with a Sector Outperform and raises the price target from $35 to $40.

Scotiabank Maintains Sector Outperform on CenterPoint Energy, Raises Price Target to $40

Scotiabank analyst Andrew Weisel maintains CMS Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) with a Sector Outperform and raises the price target from $77 to $81.

Scotiabank Maintains Sector Outperform on CMS Energy, Raises Price Target to $81

Biotech

General

Medtronic Receives U.S FDA Approval For The Omniasecure Defibrillation Lead For Placement Within The Right Ventricle

Scotiabank analyst Andrew Weisel maintains FirstEnergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>) with a Sector Outperform and raises the price target from $44 to $46.

Scotiabank Maintains Sector Outperform on FirstEnergy, Raises Price Target to $46

Scotiabank analyst Patrick Colville maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Sector Perform and lowers the price target from $240 to $160.

Scotiabank Maintains Sector Perform on MongoDB, Lowers Price Target to $160

Scotiabank analyst Sung Ji Nam maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform and lowers the price target from $650 to $605.

Scotiabank Maintains Sector Perform on Thermo Fisher Scientific, Lowers Price Target to $605

CHTR moves higher after an early reversal for a gain of 3.6% in the session
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/25201016/Screenshot-2025-04-25-at-4.09.46%E2%80%AFPM-975x1024.png" alt="" class="wp-image-11655" style="width:920px;height:auto" /></figure>
Charter Communications, Inc. (CHTR) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:13 AM on April 24th, a significant trading signal occurred for Charter Communications, Inc. (CHTR) as it demonstrated a Power Inflow at $361.02. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Charter&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Charter&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for CHTR, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $361.02. The returns on the High price ($373.92) and Close price ($373.65) after the Power Inflow are respectively 3.6% and 3.5%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.They were close today but that is not always the case
Results are not indicative of future results

Equities

WIIM

Technicals

Opinion

Signals

CHTR

Charter Communications Stock Rises 3.6% After Key Signal

Maxim Group analyst Tate Sullivan maintains Icon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) with a Buy and lowers the price target from $12 to $4.5.

ICON

Maxim Group Maintains Buy on Icon Energy, Lowers Price Target to $4.5

<a href="https://www.wsj.com/politics/policy/trump-tariff-trade-negotiations-phased-approach-7b8380a1">https://www.wsj.com/politics/policy/trump-tariff-trade-negotiations-phased-approach-7b8380a1</a>

'Trump Administration Lays Out Roadmap to Streamline Tariff Talks'- Wall Street Journal

Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) has outperformed the market over the past 5 years by 24.8% on an annualized basis producing an average annual return of 38.82%. Currently, Cloudflare has a market capitalization of $41.93 billion. 
Buying $1000 In NET: If an investor had bought $1000 of NET stock 5 years ago, it would be worth $4,944.83 today based on a price of $121.00 for NET at the time of writing.
<h3>Cloudflare's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745616636_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cloudflare Stock In The Last 5 Years

Lake Street analyst Eric Martinuzzi initiates coverage on American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) with a Buy rating and announces Price Target of $30.

Comments

iShares MSCI UAE ETF

Notizie

Ultime notizie per iShares MSCI UAE ETF (NASDAQ:UAE)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO